This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Treatment

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Management of the disease involves:

  • identifying and eliminating the underlying cause
    • discontinue topical steroids or any other facial cream which may have caused the symptoms
    • patients should be warned about worsening of symptoms for few days before starting to improve following withdrawal of steroid cream
  • wash hands after application of topical steroids at a site distant to the face (in eczema) to avoid transfer on to the face
  • treatment in
    • milder cases is with a topical antibiotic e.g. - clindamycin, erythromycin or metronidazole
    • other patients - systemic antibiotics (adult doses) e.g. - tetracycline (oxytetracycline 500 mg BD an hour before food, lymecycline 408 mg OD an hour before food) for 4-6 weeks or erythromycin 500mg BD
  • recurrent symptoms can be managed in the same method (1)

Prognosis is excellent with adequate treatment. Untreated cases may have a fluctuating disease for months or years and if severe may result in scar formation (1).

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.